ERBB2 and cancer: Prolongation of the pharmacokinetic profiles for gemcitabine in the form of gemcitabine-(C4-amide)-[anti-HER2/neu] ultimately complements, enhances and facilitates the properties of selective “targeted” chemotherapeutic delivery, continual cancer cell membrane deposition, and progressive intracellular chemotherapeutic accumulation.